China Regenerative Medicine International (HKSE:08158) General and Admin. Expense: HK$36.82 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:08158 China Regenerative Medicine International Ltd HKSE:08158
30 GF Score
Price HK$0.23
GF Value HK$0.63
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is China Regenerative Medicine International General and Admin. Expense?

China Regenerative Medicine International HKSE:08158 30 General and Admin. Expense is HK$36.82 Mil as of Dec. 2025. GuruFocus rates HKSE:08158 with a GF Score™ of 30/100 and a GF Value™ of HK$0.63 (Possible Value Trap). The stock has 5 warning signs investors should review.

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. China Regenerative Medicine International's General and Admin. Expense for the six months ended in Dec. 2025 was HK$21.58 Mil. Its General and Admin. Expense for the trailing twelve months (TTM) ended in Dec. 2025 was HK$36.82 Mil.

China Regenerative Medicine International General and Admin. Expense Related Terms

China Regenerative Medicine International General and Admin. Expense Historical Data

* Premium members only.

The historical data trend for China Regenerative Medicine International's General and Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

China Regenerative Medicine International General and Admin. Expense Chart

China Regenerative Medicine International Annual Data
Trend Apr16 Apr17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
General and Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 43.05 22.21 38.89 44.89 36.82

China Regenerative Medicine International Semi-Annual Data
Apr16 Oct16 Apr17 Oct17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
General and Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 23.17 18.99 25.90 15.23 21.58
HKSE:08158
30GF Score
China Regenerative Medicine International Ltd HKSE:08158
General and Admin. Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

China Regenerative Medicine International General and Admin. Expense Calculation

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company.

General and Admin. Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$36.82 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a General and Admin. Expense of HK$36.82 Mil mean?
China Regenerative Medicine International (HKSE:08158) has a General and Admin. Expense of HK$36.82 Mil as of Dec. 2025. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on China Regenerative Medicine International and its competitors.
Is China Regenerative Medicine International's General and Admin. Expense too high?
China Regenerative Medicine International's current General and Admin. Expense is HK$36.82 Mil. Overall, China Regenerative Medicine International has a GF Score™ of 30/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does China Regenerative Medicine International's General and Admin. Expense compare to VRTX and REGN?
China Regenerative Medicine International's General and Admin. Expense of HK$36.82 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good General and Admin. Expense for a Biotechnology company?
A good General and Admin. Expense depends on the Biotechnology industry context. However, General and Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high General and Admin. Expense mean?
A high General and Admin. Expense can signal that a stock is expensive relative to its fundamentals. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on China Regenerative Medicine International and its competitors. China Regenerative Medicine International's current General and Admin. Expense is HK$36.82 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Regenerative Medicine International stock overvalued right now?
Based on GuruFocus' analysis, China Regenerative Medicine International (HKSE:08158) is currently considered Possible Value Trap. The stock's GF Value™ is HK$0.63, compared to a current price of HK$0.23 — trading 63.2% below its estimated fair value. The current General and Admin. Expense is HK$36.82 Mil. China Regenerative Medicine International's overall GF Score™ is 30/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is General and Admin. Expense calculated?
General and Admin. Expense is calculated from a company's financial statements. For China Regenerative Medicine International (HKSE:08158), the current General and Admin. Expense is HK$36.82 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is China Regenerative Medicine International (HKSE:08158) Overvalued in 2026?

Based on GuruFocus' analysis, China Regenerative Medicine International stock appears to be undervalued. The current stock price of HK$0.23 is trading 63.2% below its estimated GF Value™ of HK$0.63. GuruFocus considers China Regenerative Medicine International to be Possible Value Trap.

Key valuation signals for HKSE:08158:

  • General and Admin. Expense: HK$36.82 Mil
  • GF Value™: HK$0.63 vs. price of HK$0.23 (63.2% below fair value)
  • GF Score™: 30/100 with 5 warning signs

No single metric tells the full story. See the HKSE:08158 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

China Regenerative Medicine International Business Description

Address 132 Nathan Road, Suite 2310-2318, Miramar Tower, Tsim Sha Tsui, Kowloon, HKG
China Regenerative Medicine International Ltd is an investment holding company. The company is engaged in the provision of healthcare products and services. It is engaged in research and development, production and sales of tissue engineering and regenerative medicine products. The business scope of company includes tissue engineering, cosmetics, cell storage, preparation and therapy, hospitals administration and other business division. The segments of the company are Aesthetic medical and beauty services and Medical services. The majority of the company's revenue is derived from its Aesthetic medical and beauty services segment that provides medical beauty products and services. Geographically, the Hong Kong accounts for the majority of the revenue and also has a presence in PRC.
30GF Score

Get the complete analysis for HKSE:08158

General and Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$0.23
Price
HK$0.63
GF Value